Five Peptides, Graded by What Their Evidence Can Actually Support

The short version

Best Peptide is a literature desk for five research peptides that get discussed together but sit at very different points on the evidence ladder: CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide. A research peptide is a short chain of amino acids — the same building blocks as proteins, just much smaller — that is studied for a specific biological effect, usually by mimicking or blocking a natural hormone or signal.

What sets this site apart is what it does first: before describing what a peptide might do, it states how solid the evidence is that it does it. That means naming when a finding comes from a single small human trial, a rat or mouse study, or nothing more than a community forum post. Two of the five compounds here (semaglutide, and to a lesser degree retatrutide) are backed by real clinical trials. The other three (CJC-1295, ipamorelin, KPV) rest on much thinner human data, and marketing for all five routinely outruns what has actually been shown. This page, and every page linked from it, tries to keep the compound and the confidence clearly separated.

Grading the evidence, not just describing it

The organizing idea on this desk is to line up the best-evidenced research peptides across categories — growth-hormone-axis peptides, an anti-inflammatory tripeptide, and a metabolic incretin agonist — and be explicit about where each one's evidence actually stops.

• Semaglutide sits furthest up the ladder: a GLP-1 receptor agonist with multiple large, randomized, outcome-driven trials and FDA approval across several indications ^[21][23][24].
• Retatrutide is close behind mechanistically but earlier in development: Phase 2 data only, with the largest weight-loss figures reported to date for this drug class, and no Phase 3 readout yet ^[19][20].
• Ipamorelin has real human pharmacokinetic data and a single randomized controlled trial — one that missed its primary efficacy endpoint ^[8][9].
• CJC-1295 has real human GH/IGF-1 pharmacology data from small studies, but no controlled efficacy trial of any kind ^[4][5].
• KPV has a substantial and reasonably consistent rodent literature and, as far as the published record shows, no human trial at all ^[11][13][14].

That ordering is not a judgment about which compound is scientifically more interesting — KPV's mechanism is arguably the cleanest story of the five. It is a statement about what a reader is actually entitled to conclude from what has been published, which is the only question this desk tries to answer.

What are research peptides?

Peptides are chains of amino acids shorter than a full protein — as few as three residues (KPV) or as many as thirty-nine (retatrutide). Because many peptide hormones and signaling molecules occur naturally in the body — growth-hormone-releasing hormone, ghrelin, alpha-melanocyte-stimulating hormone, glucagon-like peptide-1 — synthetic analogs can be built to mimic, extend, or block those signals with more precision or a longer duration of action than the native molecule allows.

'Research peptide' is industry shorthand for a peptide sold by chemical suppliers explicitly for laboratory research use, not as an approved drug or dietary supplement. Semaglutide is the exception on this desk: it graduated from that category into full FDA approval years ago. Retatrutide is mid-transition, in Phase 3 trials but still investigational. CJC-1295, ipamorelin, and KPV remain, by regulatory status, research chemicals — sold and marketed for laboratory use, with no approved human indication anywhere. That status is not a technicality. It means no agency has verified the identity, purity, dose-response relationship, or long-term safety of what is being sold, and this site treats that fact as load-bearing rather than a footnote.

How this desk reads a claim

Three habits run through every page here. First, findings are reported in the species and population actually studied — a rat-bone-growth result is labeled as a rat result, not silently generalized to people. Second, a single study is called a single study; this desk does not treat one eleven-person pharmacokinetic trial the same as a multi-thousand-participant randomized outcome trial, even when both are 'published research.' Third, where a compound has real community-reported benefits or side effects but no controlled human trial to check them against, that gap is stated plainly rather than papered over with mechanism. None of this is medical advice, none of it recommends a dose for any person, and none of it should be read as encouragement to buy or use any of these five compounds outside a legitimate research or clinical setting.